Teva Pharmaceutical Industries Limited

Total Valuation

Teva Pharmaceutical Industries Limited carries a market capitalization of 43.09B, placing it among publicly traded companies globally. Its enterprise value stands at 48.58B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Share Statistics

Teva Pharmaceutical Industries Limited currently has 1.17B shares outstanding.

Valuation Ratios

Teva Pharmaceutical Industries Limited trades at a trailing price-to-earnings ratio of 49.71. The price-to-sales ratio is 2.03, and the price-to-book ratio stands at 4.56.

Enterprise Valuation

On an enterprise value basis, Teva Pharmaceutical Industries Limited trades at an EV/EBITDA multiple of 11.45 and an EV/FCF ratio of 14.59. The EV/Sales ratio of 2.81 reflects the premium investors are willing to pay for the company's revenue stream, while the EV/EBIT multiple of 14.94 provides insight into valuation relative to core operating earnings.

Financial Position

Teva Pharmaceutical Industries Limited maintains a current ratio of 0.88, meaning it holds 0.9x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 217.53, indicating elevated leverage, while an interest coverage ratio of 4.73 demonstrates adequate ability to service its debt obligations.

Financial Efficiency

Teva Pharmaceutical Industries Limited posts a return on equity of 9.68 and a return on invested capital of 13.09.

Taxes

Over the trailing twelve months, Teva Pharmaceutical Industries Limited has paid 12.00M in income taxes, reflecting an effective tax rate of 1.69.

Stock Price Statistics

Teva Pharmaceutical Industries Limited's stock has gained approximately 158.37989% over the past 52 weeks. The 50-day moving average sits at 32.81, while the 200-day moving average is 29.81.

Income Statement

Over the trailing twelve months, Teva Pharmaceutical Industries Limited generated 17.31B in revenue and converted that into 706.00M in net income, yielding earnings per share of 0.60. EBITDA reached 4.24B, while operating income came in at 3.25B.

Balance Sheet

Teva Pharmaceutical Industries Limited holds 3.66B in cash and equivalents against 16.87B in total debt, resulting in a net debt position of 12.94B. Total book value stands at 7.75B, with working capital of -1.89B providing operational flexibility.

Cash Flow

Teva Pharmaceutical Industries Limited produced 1.90B in operating cash flow over the past twelve months. After subtracting -550.00M in capital expenditures, free cash flow totaled 1.35B - equivalent to 1.17 per share.

Margins

Teva Pharmaceutical Industries Limited operates with a gross margin of 52.45, reflecting its pricing power and cost economics. The operating margin of 18.78 and net profit margin of 4.08 provide insight into operational efficiency.

Dividends & Yields

Scores

Teva Pharmaceutical Industries Limited posts an Altman Z-Score of 0.96, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.